

## Special Issue

# Discovery of Novel Antibiotics, 2nd Edition

### Message from the Guest Editor

The first edition of the Special Issue “Discovery of Novel Antibiotics” was published in 2021. It is a successful collection with four excellent papers and has encouraged us to open a second edition on the same topic. As a continuation of the first Special Issue, this second edition aims to present the current challenges and solutions in the development of novel antibiotics. Topics may include, but are not limited to, the following:

- Strategies based on medicinal chemistry;
- Semi-synthetic and synthetic products;
- Target-based drug discovery;
- Combinatorial biosynthesis;
- Screening of natural compounds;
- New screening methods;
- Novel cultivation methods for previously “unculturable” bacteria;
- Phage therapy.

---

### Guest Editor

Dr. Cecília R.C. Calado

Department of Chemical Engineering, ISEL—Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, Lisbon, Portugal

---

### Deadline for manuscript submissions

closed (31 January 2025)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/213567](https://mdpi.com/si/213567)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)